AI Article Synopsis

  • * The researchers synthesized a carbon nanotubes-iron oxide nanocomposite using lecithin-stabilized superparamagnetic iron oxide nanoparticles through a simple hydrothermal method.
  • * Electrochemical tests, particularly cyclic voltammetry, demonstrated that the SPIONs-CNT nanocomposite has high sensitivity and selectivity for the anti-TB drug Rifampicin, with a limit of detection of 1.178 M.

Article Abstract

It is necessary to study the possible interactions among various chemical surfaces and analytes before applying them to biological systems. We report the synthesis of carbon nanotubes-iron oxide (SPIONs-CNT) nanocomposite material by using lecithin stabilized superparamagnetic iron oxide nanoparticles (SPIONs) obtained by facile hydrothermal technique. Various characterizations of the obtained nanocomposite were carried out and electrochemical studies were performed further to study the interaction capabilities of the nanocomposite with anti-TB drug Rifampicin. Obtained results by cyclic voltammetric studies of SPIONs-CNT nanocomposite with limit of detection (LOD) of 1.178 M showed the enhanced electrochemical sensitivity and selectivity of anti-tuberculosis (anti-TB) drug Rifampicin (RIF).

Download full-text PDF

Source
http://dx.doi.org/10.1166/jnn.2020.17204DOI Listing

Publication Analysis

Top Keywords

drug rifampicin
12
spions-cnt nanocomposite
8
anti-tb drug
8
nanocomposite
5
synthesis spions-cnt
4
spions-cnt based
4
based novel
4
novel nanocomposite
4
nanocomposite effective
4
effective amperometric
4

Similar Publications

The ever-increasing drug-resistant tuberculosis (TB) has invigorated the focus on the discovery and development of novel therapeutic agents and treatment options. Thiazolidinone-based compounds have shown good antitubercular properties . Here, we report the design and synthesis of a number of new derivatives inspired by the structure of thiazolidine-2,4-dione (TZD).

View Article and Find Full Text PDF

Rifampicin and isoniazid resistance not promote fluoroquinolone resistance in Mycobacterium smegmatis.

PLoS One

January 2025

National Clinical Research Center for Infectious Diseases, Shenzhen Clinical Research Center for Tuberculosis, Shenzhen Third People's Hospital, Shenzhen, Guangdong, China.

Background: The emergence of drug-resistant Tuberculosis (TB) has made treatment challenging. Although fluoroquinolones (FQs) are used as key drugs in the treatment of multidrug-resistant tuberculosis (MDR-TB), the problem of FQs resistance is becoming increasingly serious. Rifampicin (RIF) resistance is considered a risk factor for FQs resistance.

View Article and Find Full Text PDF

Functionalized Microsphere Platform Combining Nutrient Restriction and Combination Therapy to Combat Bacterial Infections.

ACS Appl Mater Interfaces

January 2025

Animal-Derived Food Safety Innovation Team, College of Veterinary Medicine, Anhui Agricultural University, Hefei 230036, China.

The escalating prevalence of multidrug-resistant (MDR) bacterial infections has emerged as a critical global health crisis, undermining the efficacy of conventional antibiotic therapies. This pressing challenge necessitates the development of innovative strategies to combat MDR pathogens. Advances in multifunctional drug delivery systems offer promising solutions to reduce or eradicate MDR bacteria.

View Article and Find Full Text PDF

Objective: Tuberculosis (TB) is a public health problem. This study aimed to determine the growth rates and drug susceptibility levels of patients with complex (MTC) growth in cultures obtained and to compare the results with the growth rates and drug susceptibility levels found in our country and other countries. It also aimed to evaluate the results of supplementing classical methods such as Lowenstein-Jensen (LJ) with liquid TK MEDIUM and to determine the relationship between the growth rates obtained with both methods.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!